Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

BACKGROUND: Local injection of infliximab in Crohn's disease (CD) lesions may reduce the risk of rare side effects, reduce the dose, and increase the efficacy of the drug. The objective was to prospectively assess the feasibility and the safety of local injection of infliximab for the postoperative recurrence of patients with CD who were followed for at least 1 year. METHODS: In a pilot, open-label study, 8 patients with CD (3 men; median age 48 years, range 35-82 years) undergoing ileocolonoscopy were prospectively enrolled. Inclusion criteria included the following: (1) localized (<5 cm) recurrence, (2) inflammatory pattern, and (3) clinically inactive CD. At the first endoscopy, lesions were injected with infliximab (median, 30 mg; range, 8-60 mg); a control endoscopy was performed at 2 weeks in 4 patients (3 received a second injection followed by a control endoscopy at 6 weeks) and at 4 weeks in 4 patients (2 received a second injection followed by a control endoscopy at 8 weeks). OBSERVATIONS: No patients showed side effects or clinical relapse in the short term and the long term (median follow-up, 20 months; range, 14-21 months). Endoscopic score improved in 3/8 patients. The histologic scores were reduced in 4 patients, worsened in 3, and were unchanged in one patient with CD. CONCLUSIONS: Local injection of infliximab into patients with CD recurrence is feasible and safe, requiring a low dose. Present findings suggest the need of placebo-controlled trials to assess the efficacy of this new and safe procedure in subgroups of patients with CD.

Original publication

DOI

10.1016/j.gie.2005.08.047

Type

Journal article

Journal

Gastrointestinal endoscopy

Publication Date

03/2006

Volume

63

Pages

486 - 492

Addresses

Cattedra di Gastroenterologia, Dipartimento di Medicina Interna, Centro di Eccellenza per le Malattie Complesse Multifattoriali; Cattedra di Anatomia Patologica, Università degli Studi di Roma Tor Vergata, Rome, Italy.

Keywords

Humans, Crohn Disease, Recurrence, Ulcer, Gastrointestinal Agents, Antibodies, Monoclonal, Colonoscopy, Treatment Outcome, Injections, Intralesional, Follow-Up Studies, Prospective Studies, Feasibility Studies, Pilot Projects, Adult, Aged, Aged, 80 and over, Middle Aged, Female, Male